Oncogenes and Tumor Suppressor Genes in Human Malignancies

  • Christopher C. Benz
  • Edison T. Liu

Part of the Cancer Treatment and Research book series (CTAR, volume 63)

Table of contents

  1. Front Matter
    Pages i-xvii
  2. Edison Liu, Bernard Weissman
    Pages 1-13
  3. Robert A. Kratzke, Eiji Shimizu, Frederic J. Kaye
    Pages 61-85
  4. Orlo H. Clark, Quan-Yang Duh
    Pages 87-104
  5. Osama M. El-Badry, Mark A. Israel
    Pages 105-128
  6. Steven A. Miles
    Pages 129-140
  7. Adam Bagg, Jeffrey Cossman
    Pages 141-166
  8. Richard A. Van Etten
    Pages 167-192
  9. David C. Lee, Noreen C. Luetteke, Leslie A. Petch
    Pages 233-254
  10. Bradley A. Arrick, Rik Derynck
    Pages 255-264
  11. David R. Kaplan, Archibald Perkins, Deborah K. Morrison
    Pages 265-279
  12. Gregory J. Kato, Daniel S. Wechsler, Chi V. Dang
    Pages 313-325
  13. Cathy A. Finlay
    Pages 327-344
  14. Adam Golden, Mary Benedict, Allen Shearn, Narimichi Kimura, Alvaro Leone, Lance A. Liotta et al.
    Pages 345-358
  15. Back Matter
    Pages 373-382

About this book


The first edition of Oncogenes (1989) focused on several of the better known transforming mechanisms and surveyed a spectrum of solid tumors and hematologic malignancies. Several of the nearly 50 known oncogenes most relevant to human disease were examined. In contrast, this volume presents a very different profile and balance of subject material that reflects the rapidly changing field of molecular oncology and its newly emerging concepts. Among the most important discoveries of the past 4 years are the identification of nearly a dozen different tumor suppressor genes and the finding of an entirely new class of cancer-causing gene (bcl-2) that acts by inhibiting cell death rather than stimulating cell proliferation. This edition begins by reviewing selected malignancies in which our earlier search for clinically relevant oncogenes has led to more focused studies on gain-of-function and loss-of-function genetic abnormalities, as well as autocrine and paracrine growth factor loops known to regulate tumor physiology and malignant cell behavior. Curiously, many of these genetic and functional abnormalities are shared by several different tumor types and are not uniformly present in all tumors of the same type. This observation brings up molecular questions about the tissue-specific determinants that underlie individual cancers and also gives added impetus to the suggestion that molecular abnormalities (referred to as tumor markers) be included among the histopathologic features used for clinical diagnosis and manage­ ment.


DNA angiogenesis cell metastasis tumor tumorigenesis

Editors and affiliations

  • Christopher C. Benz
    • 1
  • Edison T. Liu
    • 2
  1. 1.Cancer Research InstituteUniversity of CaliforniaSan FranciscoUSA
  2. 2.Lineberger Cancer Research CenterThe University of North Carolina at Chapel HillUSA

Bibliographic information

  • DOI
  • Copyright Information Kluwer Academic Publishers 1993
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-6349-1
  • Online ISBN 978-1-4615-3088-6
  • Series Print ISSN 0927-3042
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology